Literature DB >> 31413803

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Xiaojing Lin1, Yuliana Yosaatmadja1, Maria Kalyukina1, Martin J Middleditch1, Zhen Zhang2, Xiaoyun Lu2, Ke Ding2, Adam V Patterson3,4, Jeff B Smaill3,4, Christopher J Squire1,4.   

Abstract

Aberration in FGFR4 signaling drives carcinogenesis and progression in a subset of hepatocellular carcinoma (HCC) patients, thereby making FGFR4 an attractive molecular target for this disease. Selective FGFR4 inhibition can be achieved through covalently targeting a poorly conserved cysteine residue in the FGFR4 kinase domain. We report mass spectrometry assays and cocrystal structures of FGFR4 in covalent complex with the clinical candidate BLU554 and with a series of four structurally related inhibitors that define the inherent reactivity and selectivity profile of these molecules. We further reveal the structure of FGFR1 with one of our inhibitors and show that off-target covalent binding can occur through an alternative conformation that supports targeting of a cysteine conserved in all members of the FGFR family. Collectively, we propose that rotational freedom, steric hindrance, and protein dynamics explain the exceptional selectivity profile of BLU554 for targeting FGFR4.

Entities:  

Year:  2019        PMID: 31413803      PMCID: PMC6691560          DOI: 10.1021/acsmedchemlett.9b00196

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  33 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  Irreversible protein kinase inhibitors: balancing the benefits and risks.

Authors:  Tjeerd Barf; Allard Kaptein
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

3.  A structure-guided approach to creating covalent FGFR inhibitors.

Authors:  Wenjun Zhou; Wooyoung Hur; Ultan McDermott; Amit Dutt; Wa Xian; Scott B Ficarro; Jianming Zhang; Sreenath V Sharma; Joan Brugge; Matthew Meyerson; Jeffrey Settleman; Nathanael S Gray
Journal:  Chem Biol       Date:  2010-03-26

Review 4.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

Review 5.  Protein tyrosine kinase structure and function.

Authors:  S R Hubbard; J H Till
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

6.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

Review 7.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

8.  Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

Authors:  L R Desnoyers; R Pai; R E Ferrando; K Hötzel; T Le; J Ross; R Carano; A D'Souza; J Qing; I Mohtashemi; A Ashkenazi; D M French
Journal:  Oncogene       Date:  2007-06-25       Impact factor: 9.867

9.  Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.

Authors:  Dorothy M French; Benjamin C Lin; Manping Wang; Camellia Adams; Theresa Shek; Kathy Hötzel; Brad Bolon; Ronald Ferrando; Craig Blackmore; Kurt Schroeder; Luis A Rodriguez; Maria Hristopoulos; Rayna Venook; Avi Ashkenazi; Luc R Desnoyers
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

10.  Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.

Authors:  Seiki Miura; Noboru Mitsuhashi; Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Otsuka; Atsushi Kato; Takashi Shida; Daiki Okamura; Masaru Miyazaki
Journal:  BMC Cancer       Date:  2012-02-06       Impact factor: 4.430

View more
  4 in total

1.  Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Authors:  Wuqing Deng; Xiaojuan Chen; Kaili Jiang; Xiaojuan Song; Minhao Huang; Zheng-Chao Tu; Zhang Zhang; Xiaojing Lin; Raquel Ortega; Adam V Patterson; Jeff B Smaill; Ke Ding; Suming Chen; Yongheng Chen; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2021-03-22       Impact factor: 4.345

2.  Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2.

Authors:  Guangyan Du; Jie Jiang; Qibiao Wu; Nathaniel J Henning; Katherine A Donovan; Hong Yue; Jianwei Che; Wenchao Lu; Eric S Fischer; Nabeel Bardeesy; Tinghu Zhang; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2021-06-14       Impact factor: 16.823

Review 3.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.

Authors:  Chhabi Lal Chaudhary; Dongchul Lim; Prakash Chaudhary; Diwakar Guragain; Bhuwan Prasad Awasthi; Hee Dong Park; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.